Novartis’ Entresto Gains US FDA Panel Nod For New Heart Failure Claim

 
• By Sue Sutter
metronome with heart
FDA’s cardio-renal committee voted 12-1 in favor of a new heart failure claim for Entresto. • Source: Getty

More from US FDA Performance Tracker

More from Regulatory Trackers